Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AHA In Brief: Nitinol Medical Technologies

This article was originally published in The Gray Sheet

Executive Summary

Nitinol Medical Technologies: Firm's CardioSeal septal occluder shows "a clinically successful result" in 96% of 82 patients studied, according to initial results presented at the AHA conference in Orlando by Evan Zahn, MD, Miami Children's Hospital. The study involved use of the CardioSeal to treat isolated secundum atrial septal defects "in patients considered to be candidates for open heart surgery," Nitinol says. Results from a separate study sponsored by Children's Hospital, Boston and reported by Kathy Jenkins, MD showed the device could be "an important alternative to surgery for high-risk patients" with a variety of cardiac defects such as ASD, ventricular septal defects, patent foramen ovale and fenestrated fontan," the company says...
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT009111

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel